List of Retevmo drug patents
Retevmo is owned by Loxo Oncology Inc.
Retevmo contains Selpercatinib.
Retevmo has a total of 5 drug patents out of which 0 drug patents have expired.
Retevmo was authorised for market use on 08 May, 2020.
Retevmo is available in capsule;oral dosage forms.
Retevmo can be used as treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate), treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate), treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is papillary thyroid cancer; the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is recurrent thyroid cancer; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is medullary thyroid cancer; the treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer (nsclc); treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory, wherein the cancer is differentiated thyroid cancer; treating adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive refractory differentiated thyroid cancer who require systemic therapy and are radioactive iodine-refractory, treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate); treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy.
Drug patent challenges can be filed against Retevmo from 2024-05-08.
The generics of Retevmo are possible to be released after 10 October, 2038.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10112942 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| US10584124 | LOXO ONCOLOGY INC | Crystalline forms |
Oct, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10137124 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| US10172851 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| US10786489 | LOXO ONCOLOGY INC | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carbonitrile |
Oct, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 8, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 21, 2029 |
Drugs and Companies using SELPERCATINIB ingredient
NCE-1 date: 2024-05-08
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy; Treatment of adult patients with...
Dosage: CAPSULE;ORAL
RETEVMO family patents
26
United States
7
Japan
4
Israel
4
Korea, Republic of
4
China
4
European Union
3
Australia
3
EA
3
Canada
3
Argentina
3
Brazil
3
Taiwan
2
Uruguay
2
Morocco
2
Mexico
1
Colombia
1
Ecuador
1
Croatia
1
Dominican Republic
1
Moldova, Republic of
1
Denmark
1
Spain
1
Tunisia
1
Peru
1
Saudi Arabia
1
Costa Rica
1
Chile
1
Singapore
1
Jordan
1
Portugal
1
Ukraine
1
Philippines
1
Poland
1
Slovenia
1
RS
1
Hungary
1
Lithuania
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic